Patents by Inventor Jeovanis Gil Valdes
Jeovanis Gil Valdes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230414726Abstract: A respirable aqueous pharmaceutical composition comprising a neutralizing affinity binder for a virus binding to angiotensin-converting enzyme 2 (ACE2), a buffer, and a solubilizer.Type: ApplicationFiled: November 9, 2021Publication date: December 28, 2023Inventors: György MARKO-VARGA, Yutaka SUGIHARA, Jeovanis GIL VALDÉS, Roger APPELQVIST, Johan MALM
-
Publication number: 20230151077Abstract: In the invention is provided a polypeptide comprising at least 75 amino acids and having an amino acid sequence having at least 90%, such as at least 95%, 96%, 97, 98%, or 99%, such as 100% sequence identity (% SI) with human Angiotensin-converting enzyme 2 (ACE2) (SEQ ID NO 1), for use in the treatment of COVID19, SARS, or MERS, characterized in that the polypeptide is administered pulmonary and/or nasally. Further is provided the polypeptide for use in reducing the number of active virus particles being exhaled by a treated subject infected by SARS-CoV-2, SARS-CoV, or Mers-CoV. Also a dry powder or an aerosol comprising the polypeptide.Type: ApplicationFiled: April 9, 2021Publication date: May 18, 2023Inventors: György MARKO-VARGA, Balazs DÖME, Viktoria LASZLO, Peter DÖME, Yutaka SUGIHARA, Jeovanis GIL VALDES, Roger APPELQVIST, Johan MALM
-
Patent number: 9278118Abstract: This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemotherapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomycin C, imatinib, iressa, velcade (bortezomib), cytarabine (Ara C), fludarabine and mitroxantrone. The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy.Type: GrantFiled: October 20, 2014Date of Patent: March 8, 2016Assignees: BIOREC S.A., CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIAInventors: Silvio Ernesto Perea Rodriguez, Yasser Perera Negrin, Arielis Rodríguez Ulloa, Jeovanis Gil Valdés, Yassel Ramos Gómez, Lila Rosa Castellanos Serra, Lázaro Hiram Betancourt Núñez, Aniel Sánchez Puente, Jorge Fernández de Cossio Dorta Duque, Boris Ernesto Acevedo Castro, Luis Javier González López, Vladimir Besada Pérez, Daniel Fernando Alonso, Daniel Eduardo Gomez
-
Patent number: 9226946Abstract: This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemothearapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomycin C, imatinib, iressa and velcade (bortezomib). The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy.Type: GrantFiled: September 19, 2014Date of Patent: January 5, 2016Assignees: BIOREC S.A., CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIAInventors: Silvio Ernesto Perea Rodríguez, Yasser Perera Negrín, Arielis Rodríguez Ulloa, Jeovanis Gil Valdés, Yassel Ramos Gómez, Lila Rosa Castellanos Serra, Lázaro Hiram Betancourt Núñez, Aniel Sánchez Puente, Jorge Fernández de Cossio Dorta Duque, Boris Ernesto Acevedo Castro, Luis Javier González López, Vladimir Besada Pérez, Daniel Fernando Alonso, Daniel Eduardo Gomez
-
Patent number: 9145554Abstract: This invention describes a method for treating cancer by increasing the nuclear localization of the COMMD1 protein, which is associated with decreasing or blocking the proliferation of the cancer cell. The invention is also related to the use of agents that increase nuclear localization of the COMMD1 protein, in the manufacture of a medicament for cancer therapy. These agents can be peptides or proteins, among other compounds. The invention is also related to the optimization of a peptide, coming from the sequence HARIKPTFRRLKWKKYKGKFW, to increase the nuclear localization of the protein COMMD, and thus, to increase the antitumor effect of this peptide.Type: GrantFiled: November 8, 2013Date of Patent: September 29, 2015Assignee: CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIAInventors: Maribel Guerra Valespi, Julio Raul Fernandez Masso, Alexis Musacchio Lasa, Jeovanis Gil Valdes, Osvaldo Reyes Acosta, Brizaida Maylin Oliva Arguelles
-
Publication number: 20150111832Abstract: This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemotherapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomycin C, imatinib, iressa, velcade (bortezomib), cytarabine (Ara C), fludarabine and mitroxantrone. The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy.Type: ApplicationFiled: October 20, 2014Publication date: April 23, 2015Inventors: Silvio Ernesto Perea Rodríguez, Yasser Perera Negrín, Arielis Rodríguez Ulloa, Jeovanis Gil Valdés, Yassel Ramos Gómez, Lila Rosa Castellanos Serra, Lárazo Hiram Betancourt Núñez, Aniel Sánchez Puente, Jorge Fernández de Cossio Dorta Duque, Boris Ernesto Acevedo Castro, Luis Javier González López, Vladimir Besada Pérez, Daniel Fernando Alonso, Daniel Eduardo Gomez
-
Publication number: 20150030700Abstract: This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemothearapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomycin C, imatinib, iressa and velcade (bortezomib). The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy.Type: ApplicationFiled: September 19, 2014Publication date: January 29, 2015Inventors: Silvio Ernesto Perea Rodríguez, Yasser Perera Negrín, Arielis Rodríguez Ulloa, Jeovanis Gil Valdés, Yassel Ramos Gómez, Lila Rosa Castellanos Serra, Lázaro Hiram Betancourt Núñez, Aniel Sánchez Puente, Jorge Fernández de Cossio Dorta Duque, Boris Ernesto Acevedo Castro, Luis Javier González López, Vladimir Besada Pérez, Daniel Fernando Alonso, Daniel Eduardo Gomez
-
Patent number: 8871725Abstract: This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemotherapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomicin C, imatinib, iressa and velcade (vortezomib). The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy.Type: GrantFiled: February 28, 2007Date of Patent: October 28, 2014Assignee: Centro de Ingeniería Genética y BiotecnologíaInventors: Silvio Ernesto Perea Rodriguez, Yasser Perera Negrin, Arielis Rodriguez Ulloa, Jeovanis Gil Valdés, Yassel Ramos Gómez, Lila Rosa Castellanos Serra, Lázaro Hiram Betancourt Núñez, Aniel Sánchez Puente, Jorge Fernández de Cossio Dorta Duque, Boris Ernesto Acevedo Castro, Luis Javier González López, Vladimir Besada Pérez, Daniel Fernando Alonso, Daniel Eduardo Gomez
-
Publication number: 20140206621Abstract: This invention describes a method for treating cancer by increasing the nuclear localization of the COMMD1 protein, which is associated with decreasing or blocking the proliferation of the cancer cell. The invention is also related to the use of agents that increase nuclear localization of the COMMD1 protein, in the manufacture of a medicament for cancer therapy. These agents can be peptides or proteins, among other compounds. The invention is also related to the optimization of a peptide, coming from the sequence HARIKPTFRRLKWKKYKGKFW, to increase the nuclear localization of the protein COMMD, and thus, to increase the antitumor effect of this peptide.Type: ApplicationFiled: November 8, 2013Publication date: July 24, 2014Applicant: CENTRO DE INGENIERÍA GENÉTICA Y BIOTECNOLOGÍAInventors: Maribel Guerra Vallespi, Julio Raúl Fernández Massó, Alexis Musacchio Lasa, Jeovanis Gil Valdés, Osvaldo Reyes Acosta, Brizaida Maylin Oliva Argüelles
-
Patent number: 8729226Abstract: This invention describes a method for treating cancer by increasing the nuclear localization of the COMMD1 protein, which is associated with decreasing or blocking the proliferation of the cancer cell. The invention is also related to the use of agents that increase nuclear localization of the COMMD1 protein, in the manufacture of a medicament for cancer therapy. These agents can be peptides or proteins, among other compounds. The invention is also related to the optimization of a peptide, coming from the sequence HARIKPTFRRLKWKKYKGKFW, to increase the nuclear localization of the protein COMMD, and thus, to increase the antitumor effect of this peptide.Type: GrantFiled: May 31, 2011Date of Patent: May 20, 2014Assignee: Centro de Ingenieria Genetica y BiotecnologiaInventors: Maribel Guerra Vallespi, Julio Raúl Fernández Massó, Alexis Musacchio Lasa, Jeovanis Gil Valdés, Osvaldo Reyes Acosta, Brizaida Maylin Oliva Argüelles
-
Publication number: 20130224313Abstract: This invention describes a method for treating cancer by increasing the nuclear localization of the COMMD1 protein, which is associated with decreasing or blocking the proliferation of the cancer cell. The invention is also related to the use of agents that increase nuclear localization of the COMMD1 protein, in the manufacture of a medicament for cancer therapy. These agents can be peptides or proteins, among other compounds. The invention is also related to the optimization of a peptide, coming from the sequence HARIKPTFRRLKWKKYKGKFW, to increase the nuclear localization of the protein COMMD, and thus, to increase the antitumor effect of this peptide.Type: ApplicationFiled: May 31, 2011Publication date: August 29, 2013Applicant: CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIAInventors: Maribel Guerra Vallespi, Julio Raúl Fernández Massó, Alexis Musacchio Lasa, Jeovanis Gil Valdés, Osvaldo Reyes Acosta, Brizaida Maylin Oliva Argüelles
-
Publication number: 20090312190Abstract: The present invention is related to the field of the pharmaceutical industry, and describes a conserved area on the surface of the E protein that can be used for the development of wide-spectrum antiviral molecules to be employed in the prophylaxis and/or treatment of infections due to Dengue Virus serotypes 1-4 and other flaviviruses. The invention also covers chimeric proteins to be used as vaccines or as a prophylactic or therapeutic treatment against the four serotypes of Dengue Virus and other flaviviruses.Type: ApplicationFiled: November 21, 2006Publication date: December 17, 2009Applicant: CENTRO DE INGENIERÍA GENÉTICA Y BIOTECNOLOGÍAInventors: Glay Chinea Santiago, Vivian Huerta Galindo, Alejandro Miguel Martin Dunn, Jorge Victor Gavilondo Cowley, Noralvis Fleitas Salazar, Osmany Guirola Cruz, Jeovanis Gil Valdés, Aída Zulueta Morales, Lisset Hermida Cruz, Marta Ayala Avila, Diamilé Gonzáles Roche, Rolando Paez Meireles, Patricia Gabriela Toledo Mayora, Mónica Sarria Núnez, Alexis Musacchio Lasa, Yuliet Mazola Reyes
-
Publication number: 20090130228Abstract: This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemothearapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomicin C, imatinib, iressa and velcade (vortezomib). The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy.Type: ApplicationFiled: February 28, 2007Publication date: May 21, 2009Inventors: Silvio Ernesto Perea Rodriguez, Yasser Perera Negrin, Arielis Rodriguez Ulloa, Jeovanis Gil Valdes, Yassel Ramos Gomez, Lila Rosa Castellanos Serra, Lazaro Hiram Betancourt Nunez, Aniel Sanchez Puente, Jorge Fernandez de Cossio Dorta Duque, Boris Ernesto Acevedo Castro, Luis Javier Gonzalez Lopez, Vladimir Besada Perez, Daniel Fernando Alonso, Daniel Eduardo Gomez
-
Patent number: 7244411Abstract: The present invention describes a method of selective peptide isolation for the identification and quantitative analysis of proteins in complex mixture. The method comprises the selective isolation from every protein of those peptides that neither contain arginine nor histidine (NHNR peptides), and the determination of the relative concentrations of one or several proteins in different samples from the ratio between the areas of the estimated theoretical spectra for the NHNR peptides labeled with different isotopes in each sample. The determination of the relative concentration of proteins is valid for any type of isotopic label of the NHNR peptides. The method avoids the separation and purification of the proteins present in a complex mixture, and the analysis of all peptides generated from the enzymatic digest of the samples. The method is applicable to the identification of proteins with vacunal, therapeutic and diagnostic aims.Type: GrantFiled: November 15, 2004Date of Patent: July 17, 2007Assignee: Centro de Ingenieria Genetica y BiotecnologiaInventors: Lázaro Hiram Betancourt Núñez, Jorge Fernández de Cossio Dorta-Duque, Vladimir Armando Besada Pérez, Jeovanis Gil Valdés, Luis Javier González López, Gabriel Ramón Padrón Palomares, Rolando Pajón Feyt, Félix Modesto Álvarez Gil